Measuring Growth in Big Pharma's Manufacturing Investment - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Measuring Growth in Big Pharma's Manufacturing Investment
Pharmaceutical Technology's annual manufacturing investment update shows slight gains in biopharmaceutical manufacturing and emerging markets and continued restructuring of supply networks.


Pharmaceutical Technology
Volume 36, Issue 8, pp. 38-42

GlaxoSmithKline. In March 2012, SmithKline (GSK) announced plans to invest more than 500 million ($798 million) in the UK across its manufacturing sites, which included selecting Ulverston in Cumbria as the location for the first new GSK manufacturing facility to be built in the UK in almost 40 years. The company also will invest in sites in Montrose and Irvine, Scotland.

GSK's announcement followed plans by the UK government to implement a "patent box" to encourage investment in R&D and related manufacturing in the UK by introducing a lower rate of corporation tax on profits generated from UK-owned intellectual property. Following a feasibility study conducted through 2011, GSK said it will locate a new 350 million ($559 million) biopharmaceutical manufacturing facility in Ulverston, Cumbria. Detailed planning and design of the new facility is underway with an anticipated start date for construction of 2014–2015, dependent on portfolio timing and obtaining necessary planning and related consents. Once construction starts, it is likely to take at least six years before the plant is fully operational.

GSK also reported in March 2012 that it is considering additional manufacturing investment at Ulverston, which could double the total investment at the site to approximately 700 million ($1.1 billion). GSK will invest more than 100 million ($160 million) in its two manufacturing sites in Scotland: an expansion at Montrose for key materials for its respiratory drug and aluminum adjuvants for vaccines and expanded antibiotic production capacity at Irvine. GSK will also invest in sustainable green-energy production and environmentally friendly manufacturing technologies at both sites. The company is making other investments totaling 80 million ($128 million) at its sites in Ware in Hertfordshire to increase manufacturing capacity for its respiratory-inhalation device and at Barnard Castle in County Durham to establish a dermatology-manufacturing center of excellence.

As GSK proceeds with new manufacturing investment, it continues to restructure. In 2011, GSK met its original target of 2.2 billion ($3.4 billion) in annual cost-savings and identified additional annual savings of approximately 600 million ($931 million), bringing expected total annual savings of 2.8 billion ($4.3 billion) by 2014. GSK has cut its pharmaceutical R&D footprint by more than 45% during the past three years from 494,000 m2 to 295,000 m2. During the same period, its manufacturing organization has achieved annual savings of approximately 600 million ($931 million). Since 2006, GSK has exited 19 manufacturing sites, including selling or closing four factories in 2011, thereby reducing its total number of manufacturing sites to 74.

AstraZeneca. In February 2012, AstraZeneca announced new restructuring initiatives aimed at delivering annual cost-savings of $1.6 billion by the end of 2014. The restructuring will reduce headcount by 7300. The job cuts include 1350 positions in supply-chain and manufacturing operations and 2220 positions in R&D, including ending R&D activity at sites in Sodertalje, Sweden, and Montreal.

Overall, AstraZeneca's capital expenditures on supply and manufacturing facilities were approximately $388 million in 2011 (2010: $333 million; 2009: $360 million). At the end of 2011, approximately 9600 people at 23 sites in 16 countries were working on the manufacturing and supply of products. In October 2011, AstraZeneca announced an investment of $200 million to build a manufacturing facility in China Medical City in Taizhou, Jiangsu province, China, to meet growing local demand.

Bristol-Myers Squibb. In May 2012, FDA approved Bristol-Myers Squibb's biologics manufacturing facility in Devens, Massachusetts, for commercial production of the company's arthritis drug Orencia (abatacept). The $750-million multiproduct bulk biologics manufacturing facility in Devens represented the largest capital project in the company's history.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here